Study to gather information about the optimal placement of Ra-223 in the order of different treatments in terms of the effect on patients and in terms of the use of healthcare services for the treatment of Canadian patients with prostate gland cancer which spread to other parts of the body. In order to collect this information real world data from prostate gland cancer patients from four Canadian administrative databases will be analyzed. Data collected from patients treated with their 2nd line of life-prolonging therapy for Non-Metastatic Castration Resistant Prostate Cancer (mCRPC) initiated from 01 Jan 2012 to 31 Dec 2017. For patients included in the study, all available data from the beginning for their record until death, lost to follow-up or database cut-off will be included. The index date is the date of initiation of the 2nd line life-prolonging therapy for mCRPC.
Study Type
OBSERVATIONAL
Enrollment
4,301
Follow clinical administration
Multiple Locations
Multiple Locations, Canada
Overall survival
The length of time from the date of initiation of 2nd line life-prolonging therapy to death due to any cause
Time frame: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017
Event-free survival (EFS)
The length of time from the start of 2nd line life-prolonging therapy to the earliest occurrence of one of the following: * A change in life-prolonging treatment * Death from any cause
Time frame: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017
Time to External Beam Radiation Therapy (EBRT)
From the start of the 1st life-prolonging therapy (index date) until the first use of EBRT
Time frame: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017
Total incidence of EBRT
Total number of EBRT treatments received over the course of the patient's journey starting from the initiation of 2nd line life-prolonging therapy (index date) until death.
Time frame: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017
Time to first hospitalization
Measured from the start of the 2nd line life-prolonging therapy (index date) until the first overnight hospital stay.
Time frame: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017
Number of overnight hospital stays
Measured from the initiation of 2nd line life-prolonging therapy (index date) until death
Time frame: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017
Average length of hospital stays (number of days)
Measured from the initiation of 2nd line life -prolonging therapy (index date) until death
Time frame: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017
Time to first Emergency Room (ER) visit
Measured from the start of 2nd line life-prolonging therapy (index date) until the first ER visit.
Time frame: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017
Number of visits to the ER
Measured from the initiation of 2nd line life-prolonging therapy (index date) until death
Time frame: Retrospective analysis from 01-Jan-2012 to 31-Dec-2017
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.